Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.69 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.64 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.64 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.64 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.64 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.64 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | FURIN | P09958 | 1/20 | 0.48 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Robenidine SCHEMBL571510 | 1.00 | KMT2A (0.69) | KMT2ARAB9AMAPTMEN1TAAR1 | |
| Robenidine SCHEMBL28694173 | 1.00 | KMT2A (0.69) | KMT2ARAB9AMAPTMEN1TAAR1 | |
| Robenidine SCHEMBL23858311 | 1.00 | KMT2A (0.69) | KMT2ARAB9AMAPTMEN1TAAR1 | |
| Robenidine SCHEMBL23858319 | 0.98 | KMT2A (0.72) | KMT2ARAB9AMAPTMEN1TAAR1 | |
| Robenidine SCHEMBL25169352 | 0.98 | KMT2A (0.72) | KMT2ARAB9AMAPTMEN1TAAR1 | |
| Robenidine SCHEMBL30371560 | 0.98 | KMT2A (0.72) | KMT2ARAB9AMAPTMEN1TAAR1 | |
| Robenidine SCHEMBL23858320 | 0.98 | KMT2A (0.72) | KMT2ARAB9AMAPTMEN1TAAR1 | |
| Robenidine SCHEMBL30051666 | 0.82 | KMT2A (0.55) | KMT2ARAB9AMAPTMEN1TAAR1 | |
| Hydrochloric Acid SCHEMBL11850203 | 0.81 | GRIN2D (0.59) | KMT2ARAB9AMAPTMEN1TAAR1 | |
| Hydrochloric Acid SCHEMBL11838603 | 0.81 | GRIN2D (0.59) | KMT2ARAB9AMAPTMEN1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147129-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | UNIVERSITAT AUTÒNOMA DE BARCELONA (ES) | 2023-05-11 | — | — | US | claimed |
| EP-4125840-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | Som Innovation Biotech, S.A. (ES) | 2023-02-08 | — | — | EP | claimed |
| WO-2021191417-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | SOM INNOVATION BIOTECH, S.A. (ES) | 2021-09-30 | — | — | WO | claimed |
| US-20230147129-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | UNIVERSITAT AUTÒNOMA DE BARCELONA (ES) | 2023-05-11 | — | — | US | disclosed |
| EP-4125840-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | Som Innovation Biotech, S.A. (ES) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021191417-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | SOM INNOVATION BIOTECH, S.A. (ES) | 2021-09-30 | — | — | WO | disclosed |
| EP-2991638-B1 | METHODS FOR TREATING BACTERIAL INFECTIONS | NEOCULI PTY LTD (AU) | 2019-06-26 | — | — | EP | disclosed |
| US-9775818-B2 | Methods for treating bacterial infections | NEOCULI PTY LTD (AU) | 2017-10-03 | — | — | US | disclosed |
| US-20170071884-A1 | METHODS FOR TREATING BACTERIAL INFECTIONS | NEOCULI PTY LTD (AU) | 2017-03-16 | — | — | US | disclosed |
| US-9539223-B2 | Methods for treating bacterial infections | NEOCULI PTY LTD (AU) | 2017-01-10 | — | — | US | disclosed |
| US-20160058717-A1 | METHODS FOR TREATING BACTERIAL INFECTIONS | NEOCULI PTY LTD (AU) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058717-A1 | METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, PIGS, CAT | KMT2A 3953/4885RAB9A 2572/4885MAPT 3792/4885 |
| US-20170071884-A1 | METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, TNF, PIGS | KMT2A 4163/4885RAB9A 2438/4885MAPT 3515/4885 |
| US-20230147129-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | SNCA, PARK7, PRNP | KMT2A 2715/4885RAB9A 364/4885MAPT 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.